Orloff, M. M., Ramelyte, E., Butler, M. O., Rutkowski, P., Guardo, L. D., Carlino, M. S., Chmielowski, B., Kennedy, L. B., Montazeri, K., Sacco, J. J., Rossi, E., Atkinson, V., Haq, R., McKean, M., Cole, G. W., Patel, H., Kwei, L., Sachdev, J. C., Beaupre, D. M., Piperno-Neumann, S. (2026). Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba9503